Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients.
We performed this study to evaluate prevalence and clinical course of hepatitis B surface antigen (HBsAg) - positive and anti-hepatitis C virus (HCV) - positive renal transplant recipients.
HBsAg positivity was 13.7 and anti-HCV positivity 12.8%. Before transplantation, the HBsAg positivity was observed in 83.5% ofthe patients, and 16.4% ofthe patients acquired HBsAg after renal transplantation.
In the HCV group, anti-HCV positivity was observed in 47.1% before transplantation, and 19.6% acquired anti-HCV after renal transplantation.
The prevalence of chronic hepatitis in the hepatitis B virus (HBV) and in the HCV groups was not different (25.7 vs. 25.5%). Among those with chronic hepatitis in the HBV group, 4 cases progressed to fulminant hepatic failure, 1 case progressed to the end-stage liver cirrhosis, and 1 case to hepato-cellular carcinoma.
However, in the HCV group, no case showed progression of chronic hepatitis.
The overall mortality in the HBV and HCV groups was 25.3 and 7.8%, respectively (p=0.001).
Among 20 fatal cases in the HBV group 9, cases were liver disease related, but no liver disease related death occurred in the HCV group.
In conclusion, HCV as well as HBV infections are quite prevalent and important causes of posttransplant chronic hepatitis, and the clinical course of anti-HCV-positive recipients is less aggressive than that of HBsAg-positive recipients.
Mots-clés Pascal : Insuffisance rénale, Homotransplantation, Rein, Hépatite virale B, Virose, Infection, Hépatite virale C, Postopératoire, Ciclosporine, Traitement, Complication, Epidémiologie, Homme, Mongoloïde, Corée, Asie, Appareil urinaire pathologie, Rein pathologie, Néphropathie, Transplantation, Chirurgie, Appareil digestif pathologie, Foie pathologie, Chimiothérapie, Immunomodulateur
Mots-clés Pascal anglais : Renal failure, Homotransplantation, Kidney, Viral hepatitis B, Viral disease, Infection, Viral hepatitis C, Postoperative, Treatment, Complication, Epidemiology, Human, Mongoloid, Korea, Asia, Urinary system disease, Renal disease, Nephropathy, Transplantation, Surgery, Digestive diseases, Hepatic disease, Chemotherapy, Immunomodulator
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0467781
Code Inist : 002B05C02G. Création : 01/03/1996.